Professor David Price
Chair of Primary Care Respiratory Med
- About
-
- Email Address
- d.price@abdn.ac.uk
- Telephone Number
- +44 (0)1224 437237
- School/Department
- School of Medicine, Medical Sciences and Nutrition
- Publications
-
Page 6 of 35 Results 126 to 150 of 858
Risk factors for corticosteroid- and antibiotic only-treated asthma attacks in the NOVELTY cohort
European Respiratory Society (ERS) International Congress., 2125Contributions to Journals: AbstractsWhat have we learnt from real-life research in asthma and COPD?: Standards and novel designs for the future
Respirology, vol. 27, no. 12, pp. 1018-1021Contributions to Journals: Comments and Debates- [ONLINE] DOI: https://doi.org/10.1111/resp.14381
Effectiveness of initiating biologics in severe asthma patients with high steroid exposure
European Respiratory Society (ERS) International Congress., 3405Contributions to Journals: AbstractsProactive Risk Management: A Novel Approach to Embedding Oral Corticosteroid Stewardship into Asthma Care
European Medical Journal - Respiratory, vol. 10, no. Supplement 2Contributions to Journals: ArticlesAdverse outcomes following initiation of oral corticosteroids for chronic obstructive pulmonary disease: long-term observational study
British Thoracic Society Winter Meeting 2022, pp. A54Contributions to Conferences: AbstractsS88 Adverse outcomes following initiation of oral corticosteroids for chronic obstructive pulmonary disease: long-term observational study
Thorax, vol. 77, no. Suppl. 1, pp. A54Contributions to Journals: AbstractsP186 Facilitators to recruiting COPD patients to an adherence intervention trial
Thorax, vol. 77, no. Suppl. 1, A182Contributions to Journals: AbstractsPoor adherence in exacerbating COPD patients: magnitude and related factors at baseline in the MAGNIFY pragmatic trial
British Thoracic Society Winter Meeting 2022, pp. A72-A73Contributions to Journals: AbstractsDupilumab Treatment Leads to Sustained Reductions in Oral Corticosteroid Use in Patients With Oral Corticosteroid-Dependent Severe Asthma
CHEST 2022, pp. A1909-A1913Contributions to Journals: AbstractsCharacterization of patients in the International Severe Asthma Registry with high steroid exposure who did or did not initiate biologic therapy
Journal of Asthma and Allergy, vol. 15, no. 15, pp. 1491—1510Contributions to Journals: ArticlesPersistent Reductions in OCS Use in Patients With Severe, OCS-Dependent Asthma Treated With Dupilumab: LIBERTY ASTHMA TRAVERSE Study
AMCP Nexus 2022Contributions to Conferences: AbstractsClinical outcomes in patients with severe asthma who had or had not initiated biologic therapy: results from the CLEAR study
CHEST 2022, pp. A28-A32Contributions to Journals: AbstractsClinical Review: The suggested management pathway for urticaria in primary care
Clinical and Translational Allergy, vol. 12, no. 10, e12195Contributions to Journals: ArticlesClinical outcomes and emergency healthcare utilization in patients with severe asthma who continued, switched or stopped biologic therapy: results from the CLEAR study
CHEST Annual Meeting, pp. A23-A27Contributions to Journals: AbstractsShort-acting β2-agonist prescription patterns for asthma management in the SABINA III primary care cohort
npj Primary Care Respiratory Medicine, vol. 32, 37Contributions to Journals: ArticlesSuboptimal peak inspiratory flow and critical inhalation errors are associated with higher COPD-related healthcare costs
International journal of chronic obstructive pulmonary disease , vol. 2022, no. 17, pp. 2401-2415Contributions to Journals: ArticlesOral corticosteroids in asthma and beyond: moving forward
European Respiratory Journal, vol. 60, no. 3, 2200776Contributions to Journals: EditorialsPatients with Chronic Obstructive Pulmonary Disease and Evidence of Eosinophilic Inflammation Experience Exacerbations Despite Receiving Maximal Inhaled Maintenance Therapy
International journal of chronic obstructive pulmonary disease , vol. 2022, no. 17, pp. 2187—2200Contributions to Journals: ArticlesSociodemographic and clinical characteristics of patients with asthma who were prescribed ≥3 SABA canisters/year in the SABINA International study
European Respiratory Society (ERS) International Congress., pp. 2374Contributions to Conferences: AbstractsOral corticosteroid (OCS) risk predictor for Type II Diabetes in asthma
European Respiratory Society (ERS) International Congress., 4420Contributions to Journals: AbstractsSociodemographic and clinical characteristics of patients with asthma who were prescribed ≥3 SABA canisters/year in the SABINA International study
European Respiratory Society (ERS) International Congress., 3397Contributions to Journals: AbstractsMortality Analyses on Systemic Corticosteroid Use: a Long-term Observational Study
BTS Winter Meeting 2021, pp. A7-A8Contributions to Journals: Abstracts- [ONLINE] DOI: https://doi.org/10.1136/thorax-2021-BTSabstracts.11
- [OPEN ACCESS] http://aura.abdn.ac.uk/bitstream/2164/23330/1/Xu_etal_BTS2021_Mortality_Analyses_On_AAM.pdf
- [ONLINE] https://www.brit-thoracic.org.uk/document-library/winter-meetings/winter-meeting-2021/winter-meeting-2021-abstract-programme/
Persistent Reductions in OCS Use in Patients With Severe, OCS-Dependent Asthma Treated With Dupilumab: LIBERTY ASTHMA TRAVERSE Study
17th Annual Deutscher Allergiekongress (DAK) 2022, pp. 212Contributions to Journals: AbstractsPersistent Reductions in OCS Use in Patients With Severe, OCS-Dependent Asthma Treated With Dupilumab: LIBERTY ASTHMA TRAVERSE Study
Eastern Pulmonary Conference 2022Contributions to Conferences: Abstracts- [ONLINE] Conference Abstracts
A pragmatic primary practice approach to using specific IgE in allergy testing in asthma diagnosis, management, and referral
Journal of Asthma and Allergy, vol. 2022, no. 15, pp. 1069—1080Contributions to Journals: Articles